# Combined Treatment of RFA and Sorafenib on Recurrent HCC

> **NCT01470495** · NA · UNKNOWN · sponsor: **Southwest Hospital, China** · enrollment: 430 (estimated)

## Conditions studied

- HCC
- Radiofrequency Ablation
- Sorafenib

## Interventions

- **OTHER:** RFA + Sorafenib
- **OTHER:** RFA

## Key facts

- **NCT ID:** NCT01470495
- **Lead sponsor:** Southwest Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470495, "Combined Treatment of RFA and Sorafenib on Recurrent HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01470495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*